骨粗鬆症治療薬の世界市場2020-2026:投与経路別(経口、注射、その他)、薬物等級別、地域別

◆英語タイトル:Global Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Region, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT043
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年5月31日
◆ページ数:173
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、イギリス、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、アラブ首長国連邦、サウジアラビア、南アフリカ、ナイジェリア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD3,600 ⇒換算¥388,800見積依頼/購入/質問フォーム
Global License(法人利用)USD6,048 ⇒換算¥653,184見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、骨粗鬆症治療薬の世界市場について、市場範囲・調査手法、市場概要、投与経路別(経口、注射、その他)分析、薬物等級別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・骨粗鬆症治療薬の世界市場規模:投与経路別(経口、注射、その他)
・骨粗鬆症治療薬の世界市場規模:薬物等級別
・骨粗鬆症治療薬の世界市場規模:地域別
・企業概要
【レポートの概要】

The Global Osteoporosis Drugs Market size is expected to reach $10.9 billion by 2026, rising at a market growth of 4.4% CAGR during the forecast period. Osteoporosis is defined as a medical condition that is characterized by low bone density and quality in humans. Bones are brittle in this medical state, which renders them more vulnerable and, in effect, more susceptible to fractures. The condition is caused by the overproduction of a hormone called parathyroid.

The condition may lead to severe fractures, which may have harmful effects on the health of the patient. Nevertheless, the condition requires treatment, including the use of osteoporosis medications. Many of the drugs on the market include selective estrogen inhibitor modulator (SERM) bisphosphonates, parathyroid hormone treatment, calcitonin, and RANK ligand inhibitors. These drugs are administered through different routes in the body, like orally or intravenously.

International Osteoporosis Foundation reports that about 200 million people worldwide suffer from osteoporosis disorder. Currently, it is believed that about 200 million people globally suffer from this illness. About 30% of the postmenopausal people have osteoporosis in the US and Europe. According to the National Institute of Health, about 53 million people in the US are either suffering from osteoporosis or at elevated risk due to low bone density. The rising consumer base for osteoporosis disorders means steady demand development over the projected period.
Bisphosphonates are a type of drug used to reduce deterioration of the bone structure and to treat osteoporosis and related diseases. These are the most widely used medications used for the treatment of osteoporosis. They are called bisphosphonates because they have two groups of PO(OH) phosphonates. They are sometimes called diphosphonates (bis-or di-+phosphonates). Data shows that they reduce the likelihood of fracture in postmenopausal women with osteoporosis.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company.

Strategies deployed in Osteoporosis Drugs Market

2019-Apr: Amgen and UCB announced that the U.S. Food and Drug Administration (FDA) approved EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.
2018-May: Amgen got the U.S. Food and Drug Administration (FDA) approval for the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
2017-Oct: Novartis signed an agreement with Daewoong Pharmaceutical. Under this agreement, the latter company has acquired marketing and commercial rights for an osteoporosis drug from Sandoz, Novartis’ generic division. By acquiring these rights, Daewoong strengthened its product lineup and secure a steady cash-flow.
2016-Sep: Amgen extended its collaboration with Dr. Reddy’s Laboratories Ltd. Following the expansion, Dr. Reddy was aimed to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis.
2016-Jun: Amgen came into partnership with Zuellig Pharma following which the latter company helps the former company in driving growth of products and therapies in multiple markets across Asia. Zuellig was aimed to support Amgen with a range of services including Commercialization, Regulatory Services and Distribution. The partnership includes the commercialization of Amgen’s oncology therapeutics Neupogen, Neulastim, Vectibix, and XGEVA, and Amgen’s osteoporosis medicine Prolia, in nine Asian markets.

Scope of the Study
Market Segmentation:

By Route of Administration
• Oral
• Injectable and
• Other Route of Administration

By Drug Class
• Bisphosphonates
• Rank Ligand Inhibitors
• Parathyroid Hormone Therapy
• Calcitonin
• Selective Estrogen Inhibitors Modulator (SERM) and
• Other Drug Classes

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC (GSK)
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Allergan PLC
• Eli Lilly and Company

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Osteoporosis Drugs Market, by Route of Administration
1.4.2 Global Osteoporosis Drugs Market, by Drug Class
1.4.3 Global Osteoporosis Drugs Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Osteoporosis Drugs Market by Route of Administration
3.1 Global Oral Market by Region
3.2 Global Injectable Market by Region
3.3 Global Other Route of Administration Market by Region
Chapter 4. Global Osteoporosis Drugs Market by Drug Class
4.1 Global Bisphosphonates Market by Region
4.2 Global Rank Ligand Inhibitors Market by Region
4.3 Global Parathyroid Hormone Therapy Market by Region
4.4 Global Calcitonin Market by Region
4.5 Global Selective Estrogen Inhibitors Modulator (SERM) Market by Region
4.6 Global Other Drug Class Market by Region
Chapter 5. Global Osteoporosis Drugs Market by Region
5.1 North America Osteoporosis Drugs Market
5.1.1 North America Osteoporosis Drugs Market by Route of Administration
5.1.1.1 North America Oral Market by Country
5.1.1.2 North America Injectable Market by Country
5.1.1.3 North America Other Route of Administration Market by Country
5.1.2 North America Osteoporosis Drugs Market by Drug Class
5.1.2.1 North America Bisphosphonates Market by Country
5.1.2.2 North America Rank Ligand Inhibitors Market by Country
5.1.2.3 North America Parathyroid Hormone Therapy Market by Country
5.1.2.4 North America Calcitonin Market by Country
5.1.2.5 North America Other Drug Class Market by Country
5.1.3 North America Osteoporosis Drugs Market by Country
5.1.3.1 US Osteoporosis Drugs Market
5.1.3.1.1 US Osteoporosis Drugs Market by Route of Administration
5.1.3.1.2 US Osteoporosis Drugs Market by Drug Class
5.1.3.2 Canada Osteoporosis Drugs Market
5.1.3.2.1 Canada Osteoporosis Drugs Market by Route of Administration
5.1.3.2.2 Canada Osteoporosis Drugs Market by Drug Class
5.1.3.3 Mexico Osteoporosis Drugs Market
5.1.3.3.1 Mexico Osteoporosis Drugs Market by Route of Administration
5.1.3.3.2 Mexico Osteoporosis Drugs Market by Drug Class
5.1.3.4 Rest of North America Osteoporosis Drugs Market
5.1.3.4.1 Rest of North America Osteoporosis Drugs Market by Route of Administration
5.1.3.4.2 Rest of North America Osteoporosis Drugs Market by Drug Class
5.2 Europe Osteoporosis Drugs Market
5.2.1 Europe Osteoporosis Drugs Market by Route of Administration
5.2.1.1 Europe Oral Market by Country
5.2.1.2 Europe Injectable Market by Country
5.2.1.3 Europe Other Route of Administration Market by Country
5.2.2 Europe Osteoporosis Drugs Market by Drug Class
5.2.2.1 Europe Bisphosphonates Market by Country
5.2.2.2 Europe Rank Ligand Inhibitors Market by Country
5.2.2.3 Europe Parathyroid Hormone Therapy Market by Country
5.2.2.4 Europe Calcitonin Market by Country
5.2.2.5 Europe Other Drug Class Market by Country
5.2.3 Europe Osteoporosis Drugs Market by Country
5.2.3.1 Germany Osteoporosis Drugs Market
5.2.3.1.1 Germany Osteoporosis Drugs Market by Route of Administration
5.2.3.1.2 Germany Osteoporosis Drugs Market by Drug Class
5.2.3.2 UK Osteoporosis Drugs Market
5.2.3.2.1 UK Osteoporosis Drugs Market by Route of Administration
5.2.3.2.2 UK Osteoporosis Drugs Market by Drug Class
5.2.3.3 France Osteoporosis Drugs Market
5.2.3.3.1 France Osteoporosis Drugs Market by Route of Administration
5.2.3.3.2 France Osteoporosis Drugs Market by Drug Class
5.2.3.4 Russia Osteoporosis Drugs Market
5.2.3.4.1 Russia Osteoporosis Drugs Market by Route of Administration
5.2.3.4.2 Russia Osteoporosis Drugs Market by Drug Class
5.2.3.5 Spain Osteoporosis Drugs Market
5.2.3.5.1 Spain Osteoporosis Drugs Market by Route of Administration
5.2.3.5.2 Spain Osteoporosis Drugs Market by Drug Class
5.2.3.6 Italy Osteoporosis Drugs Market
5.2.3.6.1 Italy Osteoporosis Drugs Market by Route of Administration
5.2.3.6.2 Italy Osteoporosis Drugs Market by Drug Class
5.2.3.7 Rest of Europe Osteoporosis Drugs Market
5.2.3.7.1 Rest of Europe Osteoporosis Drugs Market by Route of Administration
5.2.3.7.2 Rest of Europe Osteoporosis Drugs Market by Drug Class
5.3 Asia Pacific Osteoporosis Drugs Market
5.3.1 Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.3.1.1 Asia Pacific Oral Market by Country
5.3.1.2 Asia Pacific Injectable Market by Country
5.3.1.3 Asia Pacific Other Route of Administration Market by Country
5.3.2 Asia Pacific Osteoporosis Drugs Market by Drug Class
5.3.2.1 Asia Pacific Bisphosphonates Market by Country
5.3.2.2 Asia Pacific Rank Ligand Inhibitors Market by Country
5.3.2.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
5.3.2.4 Asia Pacific Calcitonin Market by Country
5.3.2.5 Asia Pacific Other Drug Class Market by Country
5.3.3 Asia Pacific Osteoporosis Drugs Market by Country
5.3.3.1 China Osteoporosis Drugs Market
5.3.3.1.1 China Osteoporosis Drugs Market by Route of Administration
5.3.3.1.2 China Osteoporosis Drugs Market by Drug Class
5.3.3.2 India Osteoporosis Drugs Market
5.3.3.2.1 India Osteoporosis Drugs Market by Route of Administration
5.3.3.2.2 India Osteoporosis Drugs Market by Drug Class
5.3.3.3 Japan Osteoporosis Drugs Market
5.3.3.3.1 Japan Osteoporosis Drugs Market by Route of Administration
5.3.3.3.2 Japan Osteoporosis Drugs Market by Drug Class
5.3.3.4 South Korea Osteoporosis Drugs Market
5.3.3.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
5.3.3.4.2 South Korea Osteoporosis Drugs Market by Drug Class
5.3.3.5 Singapore Osteoporosis Drugs Market
5.3.3.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
5.3.3.5.2 Singapore Osteoporosis Drugs Market by Drug Class
5.3.3.6 Malaysia Osteoporosis Drugs Market
5.3.3.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
5.3.3.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
5.3.3.7 Rest of Asia Pacific Osteoporosis Drugs Market
5.3.3.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.3.3.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class
5.4 LAMEA Osteoporosis Drugs Market
5.4.1 LAMEA Osteoporosis Drugs Market by Route of Administration
5.4.1.1 LAMEA Oral Market by Country
5.4.1.2 LAMEA Injectable Market by Country
5.4.1.3 LAMEA Other Route of Administration Market by Country
5.4.2 LAMEA Osteoporosis Drugs Market by Drug Class
5.4.2.1 LAMEA Bisphosphonates Market by Country
5.4.2.2 LAMEA Rank Ligand Inhibitors Market by Country
5.4.2.3 LAMEA Parathyroid Hormone Therapy Market by Country
5.4.2.4 LAMEA Calcitonin Market by Country
5.4.2.5 LAMEA Other Drug Class Market by Country
5.4.3 LAMEA Osteoporosis Drugs Market by Country
5.4.3.1 Brazil Osteoporosis Drugs Market
5.4.3.1.1 Brazil Osteoporosis Drugs Market by Route of Administration
5.4.3.1.2 Brazil Osteoporosis Drugs Market by Drug Class
5.4.3.2 Argentina Osteoporosis Drugs Market
5.4.3.2.1 Argentina Osteoporosis Drugs Market by Route of Administration
5.4.3.2.2 Argentina Osteoporosis Drugs Market by Drug Class
5.4.3.3 UAE Osteoporosis Drugs Market
5.4.3.3.1 UAE Osteoporosis Drugs Market by Route of Administration
5.4.3.3.2 UAE Osteoporosis Drugs Market by Drug Class
5.4.3.4 Saudi Arabia Osteoporosis Drugs Market
5.4.3.4.1 Saudi Arabia Osteoporosis Drugs Market by Route of Administration
5.4.3.4.2 Saudi Arabia Osteoporosis Drugs Market by Drug Class
5.4.3.5 South Africa Osteoporosis Drugs Market
5.4.3.5.1 South Africa Osteoporosis Drugs Market by Route of Administration
5.4.3.5.2 South Africa Osteoporosis Drugs Market by Drug Class
5.4.3.6 Nigeria Osteoporosis Drugs Market
5.4.3.6.1 Nigeria Osteoporosis Drugs Market by Route of Administration
5.4.3.6.2 Nigeria Osteoporosis Drugs Market by Drug Class
5.4.3.7 Rest of LAMEA Osteoporosis Drugs Market
5.4.3.7.1 Rest of LAMEA Osteoporosis Drugs Market by Route of Administration
5.4.3.7.2 Rest of LAMEA Osteoporosis Drugs Market by Drug Class
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨粗鬆症治療薬の世界市場2020-2026:投与経路別(経口、注射、その他)、薬物等級別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆